A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Conditions
Multiple Myeloma · Relapsed/Refractory Multiple Myeloma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
HonorHealth, Scottsdale, Arizona, United States
Contact: Study coordinator (Rizwan Khawaja, MD)Berenson Cancer Center, West Hollywood, California, United States
Contact: Study coordinator (James Berenson, MD)Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
Contact: Study coordinator (Nisha Joseph, MD)Indiana University Health, Indianapolis, Indiana, United States
Contact: Study coordinator (Attaya Suvannasankha, MD)START Midwest, Grand Rapids, Michigan, United States
Contact: Study coordinator (Andrew Sochacki, MD)Washington University/Siteman Cancer Center, St Louis, Missouri, United States
Contact: Study coordinator (Mark Schroeder, MD)University of Nebraska Medical Center, Omaha, Nebraska, United States
Contact: Study coordinator (Sarah Holstein, MD)Memorial Sloan Kettering Cancer Center, New York, New York, United States
Contact: Study coordinator (Hamza Hashmi, MD)START San Antonio, San Antonio, Texas, United States
Contact: Study coordinator (Kyriakos Papadopoulos, MD)University of Wisconsin - Carbone Cancer Center, Madison, Wisconsin, United States
Contact: Study coordinator (Natalie Callander, MD)
Study leads
Binod Dhakal, M.D.
Principal Investigator
Medical College of Wisconsin
Martin Kaiser, M.D.
Principal Investigator
The Royal Marsden
Aurore Perrot, M.D.
Principal Investigator
Universite de Toulouse